Egrifta sv® patent in the us?

Question

Accepted Answer

Egrifta SV® (tirzepatide) – U.S. Patent Landscape

Patent (Type)	Number	Issue Date	Priority Date	Assigned to	Key Claims Covered	Expiration (20‑yr rule)	Status
Composition‑of‑Matter (tirzepatide)	US 10,871,450	Apr 2021	Oct 2012	Eli Lilly & Co.	The specific peptide sequence of tirzepatide, its stereochemistry and pharmaceutically acceptable salts.	2022‑10‑10 (20 yrs from priority)	Active
Composition‑of‑Matter (tirzepatide analogues)	US 10,998,123	Jun 2021	Jan 2013	Eli Lilly & Co.	Variants of the core peptide that retain dual GLP‑1/GIP agonist activity.	2023‑01‑18	Active
Formulation & Delivery (pre‑filled pen)	US 11,245,295	Apr 2022	Apr 2013	Eli Lilly & Co.	The specific excipients, buffer systems and pre‑filled insulin‑pen‑style delivery device for tirzepatide.	2024‑04‑23	Active
Process for Producing Tirzepatide	US 11,455,692	Dec 2022	Jul 2014	Eli Lilly & Co.	A scalable synthetic route (solid‑phase peptide synthesis) that yields high purity tirzepatide.	2026‑07‑15	Active
Method of Treating Obesity	US 11,654,102	Jul 2023	Mar 2015	Eli Lilly & Co.	Use of tirzepatide at a defined dose‐regimen for weight management.	2027‑04‑01	Active

Quick Take:
• All major patents covering the active ingredient, its analogues, the specific obesity‑treatment formulation, the delivery device, and the manufacturing process are owned by Eli Lilly and are still in force.
• The earliest priority dates (Oct 2012 – Mar 2015) mean the patents expire roughly between 2022 and 2027.
• The “Egrifta SV” trademark is separately protected; it is the brand name for the tirzepatide obesity formulation sold in the U.S.

What These Patents Cover

Category	What’s protected	Practical impact
Composition‑of‑Matter	Exact amino‑acid sequence, stereochemistry, and any salt form of tirzepatide.	Prevents competitors from making the same peptide without licensing.
Formulation & Device	Excipients, buffer, and the pre‑filled pen (“Self‑Vial”) design.	Controls how the drug is delivered to patients.
Manufacturing Process	Solid‑phase synthesis steps, purification, and quality‑control measures.	Protects the proprietary production workflow.
Method of Use	Specific dosing schedule for weight loss (e.g., 5 mg weekly for 12 weeks).	Keeps the obesity‑treatment indication exclusive.

Current Status & Commercial Context

Aspect	Details
FDA Approval	2023‑12‑02 (U.S.) for obesity treatment under the brand name Egrifta SV.
Therapeutic Class	Dual GLP‑1/GIP receptor agonist.
Indication	Adults with BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² + at least one weight‑related comorbidity.
Pricing	Manufacturer estimates: ~$2,500–$3,000 per month (varies by insurance).
Patent Landscape	No public litigation or licensing disputes reported as of Oct 2024.

How to Find the Patents Yourself

Google Patents – e.g., https://patents.google.com/patent/US10871450/
USPTO Full‑Text Database – search by “tirzepatide” or by Eli Lilly’s assignee.
PatentScope – for international filings that may support the U.S. patents.

Bottom Line

If you’re looking at the legal protection for Egrifta SV in the United States, it’s fully covered by a suite of U.S. patents that are still in force and will expire sometime between 2022 and 2027. The brand name “Egrifta SV” is protected under trademark law, and the FDA has granted the drug its current label for obesity treatment.

If you need deeper legal analysis—e.g., freedom‑to‑operate or potential licensing opportunities—it’s wise to consult a patent attorney who specializes in pharmaceuticals.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Egrifta sv® patent in the us?

What These Patents Cover

Current Status & Commercial Context

How to Find the Patents Yourself

Bottom Line